Clinical trials have shown that the use of insulin analogs [31],[33],[34] or pumps [29],[31] may be associated with a reduced risk of nocturnal or daytime hypoglycemia in patients with type 1 diabetes, while achieving good metabolic control. Here, INS is linked to type 1 diabetes mellitus.